Antibody polymath

Roche says it bought Therapeutic Human Polyclonals Inc. for $56.5 million in cash last week because the private company's PolyTarg technology for making human antibodies in rabbits is expected to provide another shot on goal when used alongside other antibody technologies.

Roche (SWX:ROG, Basel, Switzerland) has deals granting it access to human antibody technologies including UltiMAb mice from Genmab A/S (CSE:GEN, Copenhagen, Denmark) and HuCal Gold phage display from MorphoSys AG (FSE:MOR, Martinsried, Germany)...